Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Analyst
Los Angeles, USA
+5 year(s) experience
Dustin joined Datamonitor Healthcare in the summer of 2015. One of the highlights of his role has been analyzing the development of novel therapies from the early pre-clinical and clinical phases, through final approval and marketing authorization. Having been involved in cancer research as a graduate student, Dustin is fascinated by new compounds or mechanisms of action and their impact on the oncology treatment space, both from a clinical and commercial viewpoint.
He has a Bachelor of Science in Applied and Computational Mathematics and a PhD in Biological Sciences, both from the University of California, Irvine.
Datamonitor Healthcare, Biomedtracker
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Topic Coronavirus Clinical Trials
Datamonitor Healthcare
Takeda announced the submission of a New Drug Application for ixazomib, the first orally administered proteasome inhibitor for multiple myeloma. On 14 July 2015, Takeda announced the
Scrip
30 Nov 2015
Scrip
11 Nov 2015
